|
|
Vaccine Detail
|
Recombinant Vaccinia Viral Vector RO5217790 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Vaccinia Viral Vector RO5217790 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007064
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: E6, E7
- E6
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- E7
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: This is for Cervical Cancer (NCT01022346). A vaccine consisting of recombinant modified vaccinia Ankara (MVA) viral vector encoding mutated forms of the genes for the viral oncoproteins E6 and E7 derived from the human papillomavirus (HPV) type 16 and the human cytokine interleukin-2 (hIL2), with potential immunomodulating and antineoplastic activities. Upon subcutaneous administration, recombinant vaccinia viral vector RO5217790 may stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against cells expressing HPV E6 and E7, resulting in tumor cell lysis. Oncoproteins E6 and E7 have been implicated in the tumorigenesis of cervical carcinoma (NCIT_C88326).
|
| Host Response |
|
|
| References |
NCIT_C88326: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C88326]
NCT01022346: [https://clinicaltrials.gov/show/NCT01022346/]
|
|
